PD-L1 Cancer Research Results

PD-L1, Programmed Death-Ligand 1: Click to Expand ⟱
Source:
Type:
PD-L1 is a protein that plays a crucial role in the regulation of the immune system. PD-L1 helps to prevent the immune system from attacking healthy cells by binding to its receptor, PD-1, on immune cells. However, some cancer cells can exploit this mechanism by expressing high levels of PD-L1, which can help them evade immune detection.
PD-L1 has become a key target for cancer immunotherapy, particularly in the development of checkpoint inhibitors.

PD-1: Upregulated on tumor-infiltrating lymphocytes (TILs), reflecting chronic antigen exposure and an “exhausted” T cell phenotype.
PD-L1 and PD-L2: Frequently overexpressed by many tumor types (e.g., non–small cell lung cancer, melanoma, renal cell carcinoma, head and neck cancers.
Scientific Papers found: Click to Expand⟱
3323- SIL,    Anticancer therapeutic potential of silibinin: current trends, scope and relevance
- Review, Var, NA
Inflam↓, angioG↓, antiOx↑, TumMeta↓, TumCP↓, TumCCA↑, TumCD↑, α-SMA↓, p‑Akt↓, p‑STAT3↓, COX2↓, IL6↓, MMP2↓, HIF-1↓, Snail↓, Slug↓, Zeb1↓, NF-kB↓, p‑EGFR↓, JAK2↓, PI3K↓, PD-L1↓, VEGF↓, CDK4↓, CDK2↓, cycD1/CCND1↓, E2Fs↓,
3282- SIL,    Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions
- Review, NA, NA
hepatoP↑, AntiCan↑, TumCMig↓, Hif1a↓, selectivity↑, toxicity∅, *antiOx↑, *Inflam↓, TumCCA↑, P21↑, CDK4↓, NF-kB↓, ERK↓, PSA↓, TumCG↓, p27↑, COX2↓, IL1↓, VEGF↓, IGFBP3↑, AR↓, STAT3↓, Telomerase↓, Cyt‑c↑, Casp↑, eff↝, HDAC↓, HATs↑, Zeb1↓, E-cadherin↑, miR-203↑, NHE1↓, MMP2↓, MMP9↓, PGE2↓, Vim↓, Wnt↓, angioG↓, VEGF↓, *TIMP1↓, EMT↓, TGF-β↓, CD44↓, EGFR↓, PDGF↓, *IL8↓, SREBP1↓, MMP↓, ATP↓, uPA↓, PD-L1↓, NOTCH↓, *SIRT1↑, SIRT1↓, CA↓, Ca+2↑, chemoP↑, cardioP↑, Dose↝, Half-Life↝, BioAv↓, BioAv↓, BioAv↓, toxicity↝, Half-Life↓, ROS↓, FAK↓,
1001- SIL,    Silibinin down-regulates PD-L1 expression in nasopharyngeal carcinoma by interfering with tumor cell glycolytic metabolism
- in-vitro, NA, NA
TumCG↓, Glycolysis↓, OXPHOS↑, LDHA↓, lactateProd↓, i-citrate↑, Hif1a↓, PD-L1↓,
1049- SK,    Shikonin inhibits immune checkpoint PD-L1 expression on macrophage in sepsis by modulating PKM2
- in-vivo, NA, NA
TNF-α↓, IL6↓, IFN-γ↓, IL1β↓, PD-L1↓, p‑PKM2↓,
1052- TQ,    Thymoquinone Anticancer Effects Through the Upregulation of NRF2 and the Downregulation of PD-L1 in MDA-MB-231 Triple-Negative Breast Cancer Cells
- in-vitro, BC, MDA-MB-231
NRF2↑, PD-L1↓, Apoptosis↑,
3399- TQ,    Anticancer Effects of Thymoquinone through the Antioxidant Activity, Upregulation of Nrf2, and Downregulation of PD-L1 in Triple-Negative Breast Cancer Cells
- in-vitro, BC, MDA-MB-231 - NA, BC, MDA-MB-468
ROS↓, H2O2↓, Catalase↑, SOD↑, GSH↑, NQO1↑, GCLM↑, NRF2↑, PD-L1↓, GSSG↑, GPx1⇅, GPx4↓,
4538- TQ,    PD-L1_in_MDA-MB-231_Triple-Negative_Breast_Cancer_Cells">Thymoquinone Anticancer Effects Through the Upregulation of NRF2 and the Downregulation of PD‐L1 in MDA‐MB‐231 Triple‐Negative Breast Cancer Cells
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-468
antiOx↑, H2O2↓, Catalase↑, SOD↑, GSH↑, PRNP↑, NQO1↑, GCLM↑, NRF2↑, PD-L1↓, chemoPv↑, ROS↓,
1929- TQ,    Thymoquinone Suppresses the Proliferation, Migration and Invasiveness through Regulating ROS, Autophagic Flux and miR-877-5p in Human Bladder Carcinoma Cells
- in-vitro, Bladder, 5637 - in-vitro, Bladder, T24/HTB-9
tumCV↓, TumCP↓, TumCI↓, Casp↑, ROS↑, PD-L1↓, EMT↓, MMP↓, eff↓,
3141- VitC,    High-dose Vitamin C inhibits PD-L1 expression by activating AMPK in colorectal cancer
- in-vitro, CRC, HCT116
Glycolysis↓, eff↑, PD-L1↓, AMPK↑, HK2↓, NF-kB↓, Warburg↓, tumCV↓, GLUT1↓, PKM2↓, LDHA↓, CD4+↑, CD8+↑,

Showing Research Papers: 51 to 59 of 59
Prev Page 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 59

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 2,   Catalase↑, 2,   GCLM↑, 2,   GPx1⇅, 1,   GPx4↓, 1,   GSH↑, 2,   GSSG↑, 1,   H2O2↓, 2,   NQO1↑, 2,   NRF2↑, 3,   OXPHOS↑, 1,   ROS↓, 3,   ROS↑, 1,   SOD↑, 2,  

Mitochondria & Bioenergetics ⓘ

ATP↓, 1,   MMP↓, 2,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 1,   i-citrate↑, 1,   Glycolysis↓, 2,   HK2↓, 1,   lactateProd↓, 1,   LDHA↓, 2,   PKM2↓, 1,   p‑PKM2↓, 1,   SIRT1↓, 1,   SREBP1↓, 1,   Warburg↓, 1,  

Cell Death ⓘ

p‑Akt↓, 1,   Apoptosis↑, 1,   Casp↑, 2,   Cyt‑c↑, 1,   p27↑, 1,   Telomerase↓, 1,   TumCD↑, 1,  

Transcription & Epigenetics ⓘ

HATs↑, 1,   tumCV↓, 2,  

Cell Cycle & Senescence ⓘ

CDK2↓, 1,   CDK4↓, 2,   cycD1/CCND1↓, 1,   E2Fs↓, 1,   P21↑, 1,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State ⓘ

CD44↓, 1,   EMT↓, 2,   ERK↓, 1,   HDAC↓, 1,   IGFBP3↑, 1,   NOTCH↓, 1,   PI3K↓, 1,   STAT3↓, 1,   p‑STAT3↓, 1,   TumCG↓, 2,   Wnt↓, 1,  

Migration ⓘ

CA↓, 1,   Ca+2↑, 1,   E-cadherin↑, 1,   FAK↓, 1,   miR-203↑, 1,   MMP2↓, 2,   MMP9↓, 1,   PDGF↓, 1,   PRNP↑, 1,   Slug↓, 1,   Snail↓, 1,   TGF-β↓, 1,   TumCI↓, 1,   TumCMig↓, 1,   TumCP↓, 2,   TumMeta↓, 1,   uPA↓, 1,   Vim↓, 1,   Zeb1↓, 2,   α-SMA↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 2,   EGFR↓, 1,   p‑EGFR↓, 1,   HIF-1↓, 1,   Hif1a↓, 2,   VEGF↓, 3,  

Barriers & Transport ⓘ

GLUT1↓, 1,   NHE1↓, 1,  

Immune & Inflammatory Signaling ⓘ

CD4+↑, 1,   COX2↓, 2,   IFN-γ↓, 1,   IL1↓, 1,   IL1β↓, 1,   IL6↓, 2,   Inflam↓, 1,   JAK2↓, 1,   NF-kB↓, 3,   PD-L1↓, 9,   PGE2↓, 1,   PSA↓, 1,   TNF-α↓, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 3,   Dose↝, 1,   eff↓, 1,   eff↑, 1,   eff↝, 1,   Half-Life↓, 1,   Half-Life↝, 1,   selectivity↑, 1,  

Clinical Biomarkers ⓘ

AR↓, 1,   EGFR↓, 1,   p‑EGFR↓, 1,   IL6↓, 2,   PD-L1↓, 9,   PSA↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,   cardioP↑, 1,   chemoP↑, 1,   chemoPv↑, 1,   hepatoP↑, 1,   toxicity↝, 1,   toxicity∅, 1,  

Infection & Microbiome ⓘ

CD8+↑, 1,  
Total Targets: 117

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,  

Core Metabolism/Glycolysis ⓘ

SIRT1↑, 1,  

Migration ⓘ

TIMP1↓, 1,  

Immune & Inflammatory Signaling ⓘ

IL8↓, 1,   Inflam↓, 1,  
Total Targets: 5

Scientific Paper Hit Count for: PD-L1, Programmed Death-Ligand 1
8 immunotherapy
5 Baicalein
4 Thymoquinone
3 Astragalus
3 Silymarin (Milk Thistle) silibinin
2 Apigenin (mainly Parsley)
2 Curcumin
2 Aspirin -acetylsalicylic acid
2 beta-glucans
2 Baicalin
2 Chrysin
2 Ellagic acid
2 Honokiol
2 Bicarbonate(Sodium)
1 Silver-NanoParticles
1 Allicin (mainly Garlic)
1 Artemisinin
1 Ashwagandha(Withaferin A)
1 Berberine
1 Biochanin A
1 bempedoic acid
1 Boron
1 Butyrate
1 Capsaicin
1 Chlorogenic acid
1 Propolis -bee glue
1 Docosahexaenoic Acid
1 Disulfiram
1 Copper and Cu NanoParticles
1 Evodiamine
1 EGCG (Epigallocatechin Gallate)
1 Fucoidan
1 Gallic acid
1 Rapamycin
1 Licorice
1 Luteolin
1 Melatonin
1 Metformin
1 Magnetic Field Rotating
1 Magnetic Fields
1 Myricetin
1 Niclosamide (Niclocide)
1 Orlistat
1 Oxygen, Hyperbaric
1 Resveratrol
1 Rosmarinic acid
1 Germacranolide
1 Shikonin
1 Vitamin C (Ascorbic Acid)
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:243  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page